The preoperative or neoadjuvant systemic treatment represents the standard approach for women with HER2-positive breast cancer at stage II or III, to downstage tumor, allow breast conserving surgery, and avoid axillary dissection (5). The gene discussed is ERBB2; the disease is neoplasm.